Investor Documents

• Half-year financial report 2022 (in French, English version available soon)

  September 30, 2022

• Number of shares and voting rights - August 2022

  September 23, 2022

• Securities note (in French)

  September 2, 2022

• Amendment of the 2022 Universal Registration Document (in French)

  September 2, 2022

• Number of shares and voting rights - July 2022

  August 31, 2022

• Half year Report for liquidity contract - June 30, 2022

  July 28, 2022

• Number of shares and voting rights - June 2022

  July 28, 2022

• Number of shares and voting rights - May 2022

  June 20, 2022

• Number of shares and voting rights - April 2022

  May 24, 2022

• 2022 Universal Registration Document (English version now available)

  April 28, 2022

• Number of shares and voting rights - March 2022

  April 26, 2022

• Number of shares and voting rights - February 2022

  March 17, 2022

• Number of shares and voting rights - January 2022

  February 18, 2022

• Number of shares and voting rights - December 2021

  January 19, 2022

• Half year Report for liquidity contract - December 31, 2021

  January 19, 2022

• Number of shares and voting rights - November 2021

  December 16, 2021

• Number of shares and voting rights - October 2021

  November 19, 2021

• Number of shares and voting rights - September 2021

  October 21, 2021

• Half-year financial report 2021 (English translation available)

  September 30, 2021

• Number of shares and voting rights - August 2021

  September 15, 2021

• Number of shares and voting rights - July 2021

  September 2, 2021

• Amendment of the 2021 Universal Registration Document (in French)

  July 23, 2021

• Securities note (in French)

  July 23, 2021

• Half year Report for liquidity contract June 30, 2021

  July 15, 2021

• Number of shares and voting Rights June 2021

  July 15, 2021

• Number of Shares and Vote Rights - May 2021

  June 16, 2021

• Number of Shares and Vote Rights - April 2021

  May 19, 2021

• 2021 Universal Registration Document

  April 30, 2021

• Number of Shares and Vote Rights - March 2021

  April 16, 2021

• Number of Shares and Vote Rights - February 2021

  March 19, 2021

• Number of Shares and Vote Rights - January 2021

  February 18, 2021

• Half-Year Report For Liquidity Contract - December 31, 2020

  January 21, 2021

• Number of Shares and Vote Rights - December 2020

  January 21, 2021

• Number of Shares and Vote Rights - November 2020

  December 22, 2020

• Number of Shares and Vote Rights - October 2020

  November 19, 2020

• Number of Shares and Vote Rights - September 2020

  October 20, 2020

• Half-Year Financial Report 2020

  September 30, 2020

• Number of Shares and Vote Rights - August 2020

  September 15, 2020

• Number of Shares and Vote Rights - July 2020

  September 2, 2020

• Half-Year Report For Liquidity Contract - June 30, 2020

  July 21, 2020

• Number of Shares and Vote Rights - June 2020

  July 21, 2020

• Number of Shares and Vote Rights - May 2020

  June 30, 2020

• 2020 Universal Registration Document

  May 25, 2020

• Number of Shares and Vote Rights - April 2020

  May 19, 2020

• Number of Shares and Vote Rights - March 2020

  April 15, 2020

• Number of Shares and Vote Rights - February 2020

  March 19, 2020

• Number of Shares and Vote Rights - January 2020

  February 19, 2020

• Half-Year Report For Liquidity Contract - December 31, 2019

  January 23, 2020

• Number of Shares and Vote Rights - December 2019

  January 23, 2020

• Number of Shares and Vote Rights - November 2019

  December 20, 2019

• Number of Shares and Vote Rights - October 2019

  November 19, 2019

• Number of Shares and Vote Rights - September 2019

  October 9, 2019

• 2019 Half-Year Financial Report

  September 30, 2019

• Nombre d’actions composant le capital social et nombre total de droits de vote

  September 20, 2019

• Number of Shares and Vote Rights - July 2019

  September 9, 2019

• Number of Shares and Vote Rights - June 2019

  July 17, 2019

• Half-Year Report For Liquidity Contract - June 30, 2019

  July 10, 2019

• Number of Shares and Vote Rights - May 2019

  June 19, 2019

• Number of Shares and Vote Rights - April 2019

  May 20, 2019

• Number of Shares and Vote Rights - March 2019

  May 6, 2019

• 2019 Registration Document

  April 30, 2019

• Number of Shares and Vote Rights - February 2019

  March 18, 2019

• Number of Shares and Vote Rights - January 2019

  February 19, 2019

• 2019 Financial Agenda

  February 19, 2019

• Number of Shares and Vote Rights - December 2018

  January 17, 2019

• Half-Year Report For Liquidity Contract - December 31, 2018

  January 17, 2019

• Number of Shares and Vote Rights - November 2018

  December 18, 2018

• Number of Shares and Vote Rights - October 2018

  November 16, 2018

• Number of Shares and Vote Rights - September 2018

  October 16, 2018

• 2018 Half-Year Financial Report

  September 28, 2018

• First-Half 2018 Financial Results and Operations Update

  September 28, 2018

• Number of Shares and Vote Rights - August 2018

  September 26, 2018

• Number of Shares and Vote Rights - July 2018

  August 31, 2018

• Half-Year Report for Liquidity Contract - June 30, 2018

  July 20, 2018

• Number of Shares and Vote Rights (June 2018) and 2018 Financial Agenda Update

  July 20, 2018

• Number of Shares and Vote Rights - May 2018

  June 19, 2018

• Number of Shares and Vote Rights - April 2018

  May 18, 2018

• 2018 Registration Document

  April 30, 2018

• ABIVAX confirms its eligibility for the PEA-PME system - 2018

  April 6, 2018

• Number of Shares and Vote Rights - March 2018

  March 20, 2018

• 2017 Full-Year Results and Progress Report

  March 16, 2018

• Number of Shares and Vote Rights - February 2018

  March 15, 2018

• Number of Shares and Vote Rights - January 2018

  February 26, 2018

• Number of Shares and Vote Rights - December 2017

  January 26, 2018

• Number of Shares and Vote Rights - November 2017

  December 18, 2017

• 2018 Financial Agenda

  December 15, 2017

• Number of Shares and Vote Rights - October 2017

  November 14, 2017

• Number of Shares and Vote Rights - September 2017

  October 26, 2017

• 2017 Half-Year Financial Report

  September 29, 2017

• First-Half 2017 Financial Results and Update

  September 20, 2017

• ABIVAX receives French Regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis

  September 20, 2017

• Number of Shares and Vote Rights - August 2017

  September 8, 2017

• Number of Shares and Vote Rights - July 2017

  August 24, 2017

• Half-Year Report on the Liquidity Contract - June 30, 2017

  July 7, 2017

• Number of Shares and Vote Rights - June 2017

  July 7, 2017

• 2017 Registration Document

  May 11, 2017

• Number of Shares and Vote Rights - May 2017

  June 9, 2017

• 2016 Registration Document and highlights on the development stage of the portfolio

  May 11, 2017

• Number of Shares and Vote Rights - April 2017

  May 11, 2017

• Number of Shares and Vote Rights - March 2017

  April 12, 2017

• ABIVAX confirms its eligibility for the PEA-PME system - 2017

  April 3, 2017

• 2016 Full-Year Results and Progress Report

  March 15, 2017

• Number of Shares and Vote Rights - February 2017

  March 13, 2017

• Number of Shares and Vote Rights - January 2017

  February 9, 2017

• Number of Shares and Vote Rights - December 2016

  January 9, 2017

• Half-Year Report For Liquidity Contract - December 31, 2016

  January 9, 2017

• Number of Shares and Vote Rights - November 2016

  December 9, 2016

• Number of Shares and Vote Rights - October 2016

  November 8, 2016

• Number of Shares and Vote Rights - September 2016

  October 10, 2016

• Corporate update 2016

  December 19, 2016

• 2016 Registration Document

  December 19, 2016

• 2016 Half Year Financial Results and Corporate Update

  September 20, 2016

• 2016 Half-Year Financial Report

  September 20, 2016

• Number of Shares and Vote Rights - August 2016

  August 31, 2016

• Half-year report on the liquidity contract - June 30, 2016

  July 6, 2016

• 2015 Full-year Financial Report

  June 15, 2016

• Combined Annual General Meeting: Availability of Supporting Documents - 2016

  June 3, 2016

• Half-Year Report on the Liquidity Contract - December 31, 2015

  January 8, 2016

• 2016 Financial Agenda

  December 10, 2015

• 2015 Half-Year Results - €57.7 million raised on Euronext and Significant clinical progress on chronic Hepatitis B and HIV/AIDS

  September 29, 2015

• 2015 Half-Year Financial Report

  September 29, 2015

• International Offering Memorandum

  June 4, 2015

• ABIVAX Announces the Registration of its Reference Document by AMF

  May 19, 2015

• ABIVAX Launches IPO on the Regulated Market of Euronext in Paris

  June 9, 2015

• Great success of ABIVAX IPO on Euronext Paris, with €57.7 million raised

  June 23, 2015

1 ... 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19